Cerebrospinal fluid proteins in the diagnosis of Alzheimer's disease

Recent Patents on CNS Drug Discovery

Volumn 5, Issue 2, 2010, Pages 172-178

  Papaliagkas, Vasileios T ^a   Tsolaki, Magda ^a   Anogianakis, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Abeta42; Alzheimer's disease (ad); Cerebrospinal fluid (csf); Cytochrome c; Secretases; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; COPPER; CYTOCHROME C; ISOPROSTANE; ISOPROSTANE DERIVATIVE; TAU PROTEIN; ZINC;

ALZHEIMER DISEASE; ARTICLE; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; HUMAN; INFLAMMATION; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBROSPINAL FLUID PROTEINS; COGNITION DISORDERS; CYTOCHROMES C; HUMANS; INFLAMMATION MEDIATORS; ISOPROSTANES; METALS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 77953858990     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488910791213194     Document Type: Article

References (97)

1. Petrovitch H, White LR, Ross GW, Steinhorn SC, Li CY, Masaki KH, et al. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology 2001; 57(2): 226-34.
2. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV), American Psychiatric Association: Washington, D.C. 1994.
3. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-92.
4. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6(3):131-44.
5. Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis 2009; 18(2): 413-7.
6. Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, et al. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004; 111(3): 247-72.
7. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001; 24(1-3): 87-97.
8. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: Discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol 2003; 10(2): 119-28.
9. Andreasen N, Gottfries J, Vanmechelen E, Davidsson P, Blennow K, Vanderstichele H, et al. Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 71(4): 557-8.
10. Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 1993; 88(3): 221-3.
11. Drubin DG, Kirschner MW. Tau protein function in living cells. Cell Biol 1986; 103(6 Pt 2): 2739-46.
12. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986; 83(13): 4913-7.
13. Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999; 53(7):1488-94.
14. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010; 45(1): 30-40.
15. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using b-amyloid(1-42) and tau levels in CSF. Neurology 1999; 52(8): 1555-62.
16. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 2007; 12(3): 255-60.
17. Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P. Diagnosing prodromal Alzheimer's disease; Role of CSF biochemical markers. Mech Ageing Dev 2006;127: 129-32.
18. Ivanoiu A, Sindic CJ. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: Prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase 2005; 11(1): 32-9.
19. Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, et al. CSF phosphorylated tau protein and mild cognitive impairment: A prospective study. Exp Neurol 2000; 166(1): 201-3.
20. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2000; 2(3-4):199-206.
21. Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997; 225(3): 210-2.
22. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. Neurorx 2004; 1(2): 213-25.
23. Schönknecht P, Pantel J, Kaiser E, Thomann P, Schröder J. Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia. Neurosci Lett 2007; 416(1): 39-42.
24. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009; 50(9):1464-70.
25. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009; 1(8-9): 371-80.
26. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 1996; 86(1): 147-57.
27. Iqbal K, Adel AC, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Tau pathology in Alzheimer disease and other tauopathy. Biochim Biophys Acta 2005; 1739(2-3):198-210.
28. Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, Iqbal K, et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: An ultrasensitive bienzyme-substrate-recycle enzyme-linked immuno-sorbent assay. Am J Pathol 2002; 160(4):1269-78.
29. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver B, Van Der Perre B, Sjögren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285(1): 49-52.
30. Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000; 287(3):187-90.
31. Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park J-M, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999; 270(2): 91-4.
32. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006; 27(3): 394-401.
33. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2009; 30(5): 682-90.
34. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59(8): 1267-72.
35. Abeta42 molecularstructure. Available at: www.chemblink.com/structures/107761-42-2.gif (Accessed on: April 15, 2010).
36. Strozyk D, Blennow K, White LR, Launer LJ. CSF A_42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60: 652-6.
37. Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000; 54(9): 1875-6.
38. Gomez-Tortosa E, Gonzalo I, Fanjul S, José Sainz M, Cantarero S, Cemillán C, et al. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 2003; 60: 1218-22.
39. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schröter A, Ratzka P, et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000; 54(5):1099-102.
40. Sjögren M, Minthon L, Davidsson P, Granérus AK, Clarberg A, Vanderstichele H, et al. CSF levels of tau,-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000; 107(5): 563-79.
41. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, et al. Cerebrospinal fluid tau and A-beta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999; 273(1): 5-8.
42. Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, et al. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 2001; 172(2): 433-6.
43. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302(4): 385-93.
44. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High tau cerebrospinal fluid and low amyloid b42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55: 937-45.
45. Ganzer S, Arlt S, Schoder V, Buhmann C, Mandelkow EM, Finckh U, et al. CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: Combination of CSF-tau and MMSE yields highest sensitivity and specificity. J Neural Transm 2003; 110(10): 1149-60.
46. Jensen M, Schröder J, Blomberg M, Engvall B, Pantel J, Ida N, et al. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 1999; 45(4): 504-11.
47. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38(4): 643-8.
48. Southwick PC, Yamagata SK, Echols CL Jr, Higson GJ, Neynaber SA, Parson RE, et al. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem 1996; 66(1): 259-65.
49. Giedraitis V, Sundelöf J, Irizarry MC, Gårevik N, Hyman BT, Wahlund LO, et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett 2007; 427(3): 127-31.
50. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2008; 31(3): 357-67.
51. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 2008; 29(1): 1-11.
52. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65(4): 403-13.
53. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 2006; 5(3): 228-34.
54. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004; 9(7): 705-10.
55. Bouwman FH, Schoonenboom NS, Verwey NA, van Elk E, Kok A, Blankenstein M, et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 2009; 30(12): 1895-901.
56. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology 2007; 69(7): 631-9.
57. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64(3): 343-9.
58. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 2009; 8(7): 619-27.
59. Papaliagkas VT, Anogianakis G, Tsolaki MN, Koliakos G, Kimiskidis VK. Prediction of conversion from mild cognitive impairment to Alzheimer's disease by CSF cytochrome C levels and N200 latency. Curr Alzheimer Res 2009; 6(3): 279-84.
60. Papaliagkas VT, Anogianakis G, Tsolaki MN, Koliakos G, Kimiskidis VK. Progression of mild cognitive impairment to Alzheimer's disease: Improved diagnostic value of the combined use of N200 latency and beta-amyloid (1-42) levels. Dement Geriatr Cogn Disord 2009; 28(1): 30-5.
61. Papaliagkas VT, Anogianakis G, Tsolaki M, Koliakos G, Kimiskidis VK. Combination of P300 and CSF beta-Amyloid(1-42) assays may provide a potential tool in the early diagnosis of Alzheimer's disease. Curr Alzheimer Res 2009 Nov 26 [Epub ahead of print].
62. Papaliagkas V, Anogianaki A, Anogianakis G, Ilonidis G. The proteins and the mechanisms of apoptosis: A mini-review of the fundamentals. Hippokratia 2007; 11(3): 108-13.
63. Bayir H, Fadeel B, Palladino MJ, Witasp E, Kurnikov IV, Tyurina YY, et al. Apoptotic interactions of cytochrome c: Redox flirting with anionic phospholipids within and outside of mitochondria. Biochim Biophys Acta 2006; 1757(5-6): 648-59.
64. Kuwana T, Smith JJ, Muzio M, Dixit V, Newmeyer DD, Kornbluth S. Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J Biol Chem 1998; 273(26): 16589-94.
65. Gonzales DH, Neupert W. Biogenesis of mitochondrial c-type cytochromes. J Bioenerg Biomembr 1990; 22(6): 753-68.
66. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001; 21(9): 3017-23.
67. Manczak M, Jung Y, Park BS, Partovi D, Reddy PH. Time-course of mitochondrial gene expressions in mice brains: Implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J Neurochem 2004; 92(3): 494-504.
68. Pollack M, Phaneuf S, Dirks A, Leeuwenburgh C. The role of apoptosis in the normal aging brain, skeletal muscle, and heart. Ann N Y Acad Sci 2002; 959: 93-107.
69. Sullivan PG, Brown MR. Mitochondrial aging and dysfunction in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29(3): 407-10.
70. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 2008; 65(8): 1102-7.
71. Holsinger RM, McLean CA, Collins SJ, Masters CL, Evin G. Increased p-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol 2004; 55(6): 898-9.
72. Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 2007; 64(6): 718-26.
73. Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, et al. Increased CSF-BACE 1 activity is associated with ApoE- epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008; 131(Pt 5):1252-8.
74. Hampel H, Shen Y. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. Scand J Clin Lab Invest 2009; 69(1): 8-12.
75. Martínez M, Fernández-Vivancos E, Frank A, De la Fuente M, Hernanz A. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations. Brain Res 2000; 869(1-2): 216-9.
76. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson"s disease patients. Neurosci Lett 1995; 202(1-2):17-20.
77. März P, Heese K, Hock C, Golombowski S, Müller-Spahn F, Rose-John S, et al. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 1997; 239(1): 29-32.
78. Hampel H, Schoen D, Schwarz MJ, Kötter HU, Schneider C, Sunderland T, et al. Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neurosci Lett 1997; 228(3): 143-6.
79. Cacabelos R, Barquero M, García P, Alvarez XA, Varela de Seijas E. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Methods Find Exp Clin Pharmacol 1991; 13(7): 455-8.
80. Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol Sci 2006; 27(1): 33-9.
81. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: Interleukin-1beta, interleukin- 6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 1998; 12(3): 215-27.
82. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 2005; 7(1-2): 269-75.
83. Quinn JF, Montine KS, Moore M, Morrow JD, Kaye JA, Montine TJ. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis 2004; 6(1): 93-7.
84. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ 2nd. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 1998; 44(3): 410-3.
85. De Leon MJ, Mosconi L, Li J, De Santi S, Yao Y, Tsui WH, et al. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol 2007; 254(12): 1666-75.
86. Squitti R, Barbati G, Rossi L, Ventriglia M, Dal Forno G, Cesaretti S, et al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology 2006; 67(1): 76-82.
87. Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, Calabrese L, Rossi L. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals 2008; 21(3): 367-72.
88. Strozyk D, Launer LJ, Adlard PA, Cherny RA, Tsatsanis A, Volitakis I, et al. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging 2009; 30(7):1069-77.
89. Ventriglia M, Chiavetto BL, Benussi L, Binetti G, Zanetti O, et al. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Mol Psychiatry 2002; 7(2): 136-7.
90. Matsushita S, Arai H, Matsui T, Yuzuriha T, Urakami K, Masaki T, et al. Brain-derived neurotrophic factor gene polymorphisms and Alzheimer's disease. J Neural Transm 2005; 112(5): 703-11.
91. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 2007; 41(5): 387-94.
92. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 2006; 21(1): 9-15.
93. Vanderstichele, H., Vanmechelen, E., De Meyer, G., Blennow, K., Kostanjevecki, V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease. US20080057593 (2007).
94. Kerkman, D., Debernardis, J.F., Zinkowski, R., Hampel, H.J. Method for predicting whether subject with mild cognitive Impairment (MCI) will develop Alzheimer's Disease. US20090022825 (2009).
95. Hort J, Bartos A, Pirttilä T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 2009 [Epub ahead of print].
96. Novak, M. Conformationally abnormal forms of tau proteins and specific antibodies thereto. US20090123936 (2009).
97. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6(8): 734-46.